Biomed pioneer Dr. Benny Zeevi passes away at 72
Biomed pioneer Dr. Benny Zeevi passes away at 72
An expert in the field of pediatric cardiology, Dr. Zeevi worked to promote the branches of biotechnology and life sciences in Israel, was a partner in leading funds that supported these fields and served as chairman in various high-tech companies
Dr. Benny Zeevi, one of the pioneers of the biomed industry and an expert in the field of pediatric cardiology, passed away today at the age of 72. Dr. Zeevi worked extensively to promote the life sciences and biotechnology industry in Israel. He served as a Managing General Partner at Tel Aviv Venture Partners, Run Young Capital, and DFJ Tamir Fishman Ventures, where he led hundreds of investments in Israeli companies in the field of life sciences and biomed.
In addition, he served as the chairman of the board of companies such as Vessl, Kytera, Oggii, as a board member of the Kaiima company and as a board consultant for companies such as V Wave, Bionaut Labs and Data2Life. Before joining the DFJ fund in 2003, Zeevi served as vice president of business development and director of the company Card Guard AG.
Between the years 1990-1998 he was the director of the pediatric sedation unit at Schneider Children's Hospital in Beilinson and a Fellow at Harvard University Children's Hospital. Between 2012-2015 he served as co-chairman of the IATI association, in which he coordinated the activities in the field of cleantech and life sciences. He also held the position of chairman of the annual biomed conference and the DigitalHealth.IL conference which brought to Israel thousands of investors and entrepreneurs in these fields.
At the same time as his activities for Israeli entrepreneurship, Zeevi also worked in the academic field and founded the first executive program for entrepreneurs in the field of biotechnology and medical devices within the Faculty of Management of Tel Aviv University. He wrote more than 60 scientific articles and in 1993 received the Lieberman Award for his contribution to the advancement of the treatment of congenital heart diseases in children.
